guest ::
| Home > Publications Database > The effect of plasma cortisol on hippocampal atrophy and clinical progression in mild cognitive impairment. > print |
| Home > Publications Database > The effect of plasma cortisol on hippocampal atrophy and clinical progression in mild cognitive impairment. > print |
| 001 | 259918 | ||
| 005 | 20240403123632.0 | ||
| 024 | 7 | _ | |a 10.1002/dad2.12463 |2 doi |
| 024 | 7 | _ | |a pmid:37583892 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC10423926 |2 pmc |
| 024 | 7 | _ | |a altmetric:152897589 |2 altmetric |
| 037 | _ | _ | |a DZNE-2023-00803 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a White, Silke |0 P:(DE-2719)2810508 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a The effect of plasma cortisol on hippocampal atrophy and clinical progression in mild cognitive impairment. |
| 260 | _ | _ | |a Hoboken, NJ |c 2023 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1694089722_1589 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Both elevated cortisol and hippocampal volume have been linked to an increased risk for the development of Alzheimer's disease (AD). This longitudinal study assessed the effects of plasma cortisol on hippocampal atrophy and clinical progression rates in patients with mild cognitive impairment (MCI).Patients with amnestic MCI (n = 304) were selected from the Alzheimer's Disease Neuroimaging Initiative (ADNI) based on availability of baseline plasma cortisol and hippocampal volume measures, assessed at baseline and during follow-ups. We investigated associations between plasma cortisol, hippocampal volume, and risk of clinical progression to AD over a study period of up to 100 months (mean follow-up time 36.8 months) using linear mixed models, Cox proportional hazards models, and Kaplan-Meier estimators.Plasma cortisol predicted greater hippocampal atrophy, such that participants with higher cortisol showed faster decline in hippocampal volume over time (interaction: β = -0.15, p = 0.004). Small hippocampal volume predicted a higher risk of clinical progression to AD (haard ratio [HR] = 2.15; confidence in terval [CI], 1.64-2.80; p < 0.001). A similar effect was not found for cortisol (HR = 1.206; CI, 0.82-1.37; p = 0.670) and there was no statistical evidence for an interaction between hippocampal volume and cortisol on clinical progression (HR = 0.81; CI, 0.57-0.17; p = 0.260).Our findings suggest that higher cortisol predicts higher hippocampal atrophy, which in turn is a risk factor for progression to AD. Regulation of the hypothalamic-pituitary-adrenal axis through stress-reducing lifestyle interventions might be a protective factor against hippocampal degeneration at the prodromal stage of AD. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a hypothalamic‐pituitary‐adrenal axis |2 Other |
| 650 | _ | 7 | |a hypothalamic‐pituitary‐adrenal axis |2 Other |
| 650 | _ | 7 | |a ADNI |2 Other |
| 650 | _ | 7 | |a MCI |2 Other |
| 650 | _ | 7 | |a cortisol |2 Other |
| 650 | _ | 7 | |a hippocampus |2 Other |
| 650 | _ | 7 | |a hypothalamic‐pituitary‐adrenal axis |2 Other |
| 650 | _ | 7 | |a neurodegeneration |2 Other |
| 650 | _ | 7 | |a risk factor |2 Other |
| 650 | _ | 7 | |a stress |2 Other |
| 700 | 1 | _ | |a Mauer, René |b 1 |
| 700 | 1 | _ | |a Lange, Catharina |0 P:(DE-2719)9000635 |b 2 |u dzne |
| 700 | 1 | _ | |a Klimecki, Olga |0 P:(DE-2719)9002456 |b 3 |u dzne |
| 700 | 1 | _ | |a Huijbers, Willem |b 4 |
| 700 | 1 | _ | |a Wirth, Miranka |0 P:(DE-2719)2814122 |b 5 |e Last author |u dzne |
| 700 | 1 | _ | |a Initiative, Alzheimer's Disease Neuroimaging |b 6 |e Collaboration Author |
| 773 | _ | _ | |a 10.1002/dad2.12463 |g Vol. 15, no. 3, p. e12463 |0 PERI:(DE-600)2832898-X |n 3 |p e12463 |t Alzheimer's & dementia / Diagnosis, assessment & disease monitoring |v 15 |y 2023 |x 2352-8729 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/259918/files/DZNE-2023-00803.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/259918/files/DZNE-2023-00803.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:259918 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2810508 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 2 |6 P:(DE-2719)9000635 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)9002456 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2814122 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-04-16T15:13:10Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-04-16T15:13:10Z |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2022-11-11 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2022-11-11 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2021-04-16T15:13:10Z |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ALZH DEMENT-DADM : 2022 |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-26 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0112 |2 StatID |b Emerging Sources Citation Index |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-26 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ALZH DEMENT-DADM : 2022 |d 2023-10-26 |
| 920 | 1 | _ | |0 I:(DE-2719)1710011 |k AG Wirth |l Brain Resilience |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1740002 |k AG White |l Imaging Platfrom (Dresden) |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1710011 |
| 980 | _ | _ | |a I:(DE-2719)1740002 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|